NervGen Pharma Corp. filings document a Canadian clinical-stage biotechnology issuer furnishing U.S. reports as a foreign issuer. The record includes Form 6-K current reports, material change reports, and incorporation by reference into the company’s MJDS Form F-10 registration statement.
The company’s SEC disclosures cover executive appointments and resignations, employment agreements, stock option grants, board oversight, subsidiary employment arrangements through NervGen US Inc., and capital-market registration matters. These filings also provide formal records tied to governance, compensation, equity awards, and the company’s U.S. public reporting framework.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.
NervGen Pharma Corp. submitted a Form 6-K as a foreign private issuer for January 2026. The company confirms it files annual reports under Form 40-F, which is the standard for certain Canadian issuers.
Exhibit 99.1, a Material Change Report dated January 8, 2026, is included with this submission and is incorporated by reference into NervGen’s Form F-10 registration statement (File No. 333-292197). The report is signed on behalf of the company by Chief Financial Officer William J. Adams.
NervGen Pharma Corp. has filed Amendment No. 1 to a Form F-10 registration statement linked to an amended and restated Canadian short form base shelf prospectus covering up to U.S.$150,000,000 of securities. Over a 25‑month period, the company and certain securityholders may sell common shares, debt securities, subscription receipts, warrants and units in various combinations, including potential at‑the‑market distributions, with exact terms set in future prospectus supplements. NervGen is a clinical‑stage biopharmaceutical company developing neuroreparative therapies, led by NVG‑291 for spinal cord injury, and currently has no approved products or product revenue. The prospectus notes plans to list common shares on the Nasdaq Capital Market under the symbol “NGEN”, while they remain listed on the TSX‑V and OTCQB. Extensive risk disclosures highlight ongoing losses, the need for additional capital, clinical and regulatory uncertainty, and cross‑border enforcement and disclosure differences for U.S. investors.